{"product_id":"apellis-business-model-canvas","title":"Apellis Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApellis's Business Model: A Strategic Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic core of Apellis Pharmaceuticals's innovative approach to treating rare diseases. This Business Model Canvas breaks down how they identify unmet needs, develop groundbreaking therapies, and reach patient populations effectively. It's a must-have for anyone studying biopharmaceutical strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSobi Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals has a key partnership with Sobi (Swedish Orphan Biovitrum) for the global co-development and ex-U.S. commercialization of their systemic pegcetacoplan drug, marketed as Aspaveli.\u003c\/p\u003e\n\u003cp\u003eThis collaboration is significant as it provides Apellis with crucial licensing and other revenue streams. A notable aspect is a capped royalty purchase agreement, allowing Apellis to potentially receive up to $300 million in exchange for 90% of its ex-U.S. royalties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals leverages Contract Manufacturing Organizations (CMOs) for the production of its vital drug substances and finished products. This strategic reliance on external partners is crucial for scaling operations and ensuring a consistent supply of its therapies.\u003c\/p\u003e\n\u003cp\u003eFor example, Apellis has established a key partnership with Bachem Americas, Inc. to manufacture the drug substance for pegcetacoplan. Additionally, NOF Corporation serves as a critical supplier, providing the activated polyethylene glycol derivative, an essential component in pegcetacoplan’s formulation, thereby fortifying the company’s supply chain resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers \u0026amp; Physician Practices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals heavily relies on partnerships with healthcare providers and physician practices, particularly ophthalmologists, nephrologists, and hematologists. These specialists are essential for the proper administration and prescription of Apellis's innovative therapies, such as SYFOVRE injections used to treat geographic atrophy, a leading cause of blindness.  Their expertise ensures patients receive the correct dosage and understand the treatment process.\u003c\/p\u003e\n\u003cp\u003eThese medical practices act as the frontline for patient care, serving as direct touchpoints for treatment initiation and ongoing management. Their role extends beyond simple drug delivery; they are instrumental in educating patients about the benefits and potential side effects of Apellis's medications, fostering trust and adherence.  In 2024, the successful adoption of treatments like SYFOVRE is directly linked to the engagement and capabilities of these physician networks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eApellis Pharmaceuticals actively partners with patient advocacy groups to ensure patient voices are central to their strategy. This collaboration is crucial for developing therapies and resources that genuinely meet the needs of specific patient communities.\u003c\/p\u003e\n\u003cp\u003eThese partnerships help Apellis tailor clinical trial designs and patient support programs, making them more effective and relevant. For instance, by working with groups focused on rare diseases, Apellis gains invaluable insights into the daily challenges faced by patients and their caregivers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient-Centric Trial Design\u003c\/strong\u003e: Incorporating patient feedback to improve trial accessibility and relevance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Patient Support\u003c\/strong\u003e: Developing resources that address specific patient needs and improve quality of life.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommunity Engagement\u003c\/strong\u003e: Building trust and understanding within patient populations for better therapeutic adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eApellis Pharmaceuticals actively collaborates with academic and research institutions to push the boundaries of scientific understanding in the complement system. These partnerships are crucial for identifying novel therapeutic targets and validating early-stage research. For instance, in 2024, Apellis continued to support research grants and sponsored studies at leading universities, fostering a pipeline of innovative ideas.\u003c\/p\u003e\n\u003cp\u003eThese collaborations are fundamental to Apellis's strategy for driving innovation and expanding its drug development pipeline. By working with top researchers, the company gains access to cutting-edge discoveries and expertise, which helps validate its scientific approach to treating complement-mediated diseases. This synergy ensures a continuous flow of promising candidates for clinical development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eFostering Scientific Advancement:\u003c\/strong\u003e Apellis partners with institutions to explore new therapeutic applications within the complement system, driving innovation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Expansion:\u003c\/strong\u003e Collaborations are essential for identifying and validating new drug candidates, thereby growing the company's development pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eScientific Validation:\u003c\/strong\u003e These partnerships help confirm the efficacy and scientific basis of Apellis's complement-driven therapeutic strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024 Focus:\u003c\/strong\u003e The company continued to invest in research grants and sponsored studies at academic centers throughout 2024, reinforcing its commitment to external scientific partnerships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships Drive Revenue and Supply Chain Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals strategically partners with Sobi for the global co-development and ex-U.S. commercialization of systemic pegcetacoplan, generating significant licensing and royalty revenue streams.  The company also relies on Contract Manufacturing Organizations (CMOs) like Bachem Americas and NOF Corporation for the critical production of drug substances and key components, ensuring supply chain stability and scalability.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eApellis Pharmaceuticals' business model focuses on developing and commercializing novel therapies for rare diseases, leveraging its proprietary complement cascade inhibition platform to address unmet medical needs in specific patient populations.\u003c\/p\u003e\n\u003cp\u003eThis model emphasizes a patient-centric approach, targeting rare disease communities through specialized medical affairs and commercial teams, supported by strong clinical development and regulatory expertise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eApellis Pharmaceuticals' Business Model Canvas acts as a pain point reliever by clearly outlining their strategy to address unmet medical needs in rare diseases, providing a focused approach for investors and stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals' key activity in Research and Development is central to its strategy, focusing on advancing its C3 complement inhibition platform. This involves a significant investment in discovering and developing novel therapies for a range of complement-driven diseases.\u003c\/p\u003e\n\u003cp\u003eThe company is actively progressing its pipeline, with notable efforts on new candidates like APL-3007. Furthermore, Apellis is dedicated to expanding the therapeutic reach of its existing drugs into new areas, particularly in nephrology, targeting conditions such as Focal Segmental Glomerulosclerosis (FSGS) and Delayed Graft Function (DGF).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals' key activity in clinical trial execution is central to advancing its innovative therapies. This involves the meticulous design, oversight, and management of studies to gather robust data on safety and efficacy. For instance, the company is actively engaged in ongoing Phase 3 trials for EMPAVELI, targeting rare kidney diseases like C3 Glomerulopathy (C3G) and Immunoglobulin A Nephropathy (IgAN). \u003c\/p\u003e\n\u003cp\u003eFurthermore, Apellis is preparing for future clinical development, with planned Phase 3 trials for other rare kidney conditions. The company is also progressing with earlier-stage studies, including Phase 1b\/2 trials for APL-3007 in combination with SYFOVRE, demonstrating a commitment to exploring new therapeutic avenues and expanding its pipeline. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals focuses on the efficient and compliant manufacturing of its key therapies, SYFOVRE and EMPAVELI. This critical activity ensures that these life-changing treatments are produced to the highest quality standards.\u003c\/p\u003e\n\u003cp\u003eManaging relationships with contract manufacturing organizations (CMOs) is central to Apellis's manufacturing strategy. By leveraging external expertise, Apellis can scale production effectively to meet growing patient demand.\u003c\/p\u003e\n\u003cp\u003eOptimizing the supply chain is paramount for reliable patient delivery. This involves careful logistics planning to ensure that SYFOVRE and EMPAVELI reach patients when and where they are needed, a crucial aspect for therapies treating serious conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eApellis Pharmaceuticals prioritizes strong commercialization and sales efforts, particularly within the United States, to support its key therapies. This involves strategic marketing campaigns, an effective sales force, and dedicated market access programs to solidify and expand the market presence of its flagship products.  The company is keenly focused on maintaining leadership for SYFOVRE in the geographic atrophy market.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Apellis has been actively building out its commercial infrastructure. For SYFOVRE, the company reported significant uptake following its launch in early 2023, aiming to capture a substantial portion of the addressable patient population. Their sales force is trained to engage with ophthalmologists and retina specialists, emphasizing the clinical benefits and patient outcomes associated with SYFOVRE.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarketing and Promotion:\u003c\/strong\u003e Apellis employs targeted marketing strategies to raise awareness of SYFOVRE among healthcare professionals and patients, highlighting its novel mechanism of action and efficacy in slowing GA progression.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Force Deployment:\u003c\/strong\u003e A specialized sales team is dedicated to reaching key opinion leaders and prescribers in ophthalmology, ensuring broad access and understanding of the product's value proposition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access Initiatives:\u003c\/strong\u003e The company actively works with payers and insurers to secure favorable formulary placement and reimbursement for SYFOVRE, aiming to minimize barriers to patient access.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeographic Focus:\u003c\/strong\u003e The primary commercialization efforts are concentrated in the U.S. market, where Apellis has established a strong foundation for its ophthalmology franchise, with plans to expand internationally.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating complex regulatory pathways is a crucial activity for Apellis Pharmaceuticals, involving the meticulous submission of supplemental new drug applications (sNDAs) and securing vital approvals from global health authorities, most notably the U.S. Food and Drug Administration (FDA).\u003c\/p\u003e\n\u003cp\u003eRecent significant achievements underscore Apellis's proficiency in this area, including the successful approval of EMPAVELI (pegcetacoplan) for the treatment of C3 glomerulonephritis (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Submission Strategy:\u003c\/strong\u003e Developing and executing comprehensive strategies for sNDA submissions to health authorities like the FDA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApproval Acquisition:\u003c\/strong\u003e Successfully obtaining marketing authorizations for new indications and therapies, such as EMPAVELI for C3G and IC-MPGN.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-Approval Compliance:\u003c\/strong\u003e Ensuring ongoing adherence to regulatory requirements and managing any necessary post-market surveillance or studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Complement Therapies: Market Growth and Clinical Progress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eApellis Pharmaceuticals' key activities revolve around advancing its complement inhibition platform through rigorous research and development, clinical trial execution, efficient manufacturing, and robust commercialization. The company's strategic focus on developing therapies for complement-driven diseases, particularly in nephrology and ophthalmology, drives its operational priorities.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Apellis continued to expand the reach of its therapies, with SYFOVRE showing strong commercial uptake in the U.S. geographic atrophy market. The company is also progressing clinical trials for EMPAVELI in various kidney diseases, including C3G and IgAN, and exploring new candidates like APL-307. Manufacturing and supply chain optimization are critical to ensuring patient access to these treatments.\u003c\/p\u003e\n\u003cp\u003eRegulatory engagement is paramount, with Apellis securing approvals for EMPAVELI in C3G and IC-MPGN, and preparing for future submissions. This multifaceted approach, from discovery to market, defines Apellis's business model.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas preview you're viewing is the actual document you will receive upon purchase, offering a comprehensive overview of Apellis Pharmaceuticals' strategic framework. This means you're seeing the exact content, structure, and formatting that will be delivered, ensuring no surprises and full transparency in your acquisition. You'll gain immediate access to this complete, ready-to-use analysis, allowing you to delve into Apellis's key business components without delay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674801652089,"sku":"apellis-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/apellis-business-model-canvas.png?v=1755795784","url":"https:\/\/portersfiveforce.com\/products\/apellis-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}